CLINICAL TRIALS PROFILE FOR PROSTIN E2
✉ Email this page to a colleague
All Clinical Trials for PROSTIN E2
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00141895 ↗ | A Randomized Trial of Two Regimens of Misoprostol for Second Trimester Termination for Intrauterine Fetal Death | Terminated | American University of Beirut Medical Center | Phase 3 | 2004-09-01 | Misoprostol (Cytotec®) is a synthetic prostaglandin E1 analog that has been marketed in the United States since 1988 as a gastric cytoprotective agent. Despite a focused campaign by the manufacturer to curtail its use in obstetric practice, misoprostol has, over the past several years, gained widespread acceptance to effect the medical termination of pregnancy in the second trimester, either alone or after pretreatment with mifepristone. The primary reasons for this prompt incorporation into standard practice include its low cost and the lack of stringent storage requirements. Vaginal administration seems to be more efficacious than when given orally. The use of sublingual misoprostol for first trimester abortions has been extensively investigated as evidenced by the large number of publications comparing sublingual to other routes of misoprostol for first trimester pregnancy termination, on the assumption that the sublingual route would have a similar efficacy of the vaginal route. In addition, the sublingual route would combine an easier administration with the added advantage of no restriction of mobility after administration. There has been no previous report in the literature comparing the use of misoprostol given sublingually to that given vaginally for the second trimester termination following intrauterine fetal death. Our aim is to compare efficacy, safety and patient satisfaction with misoprostol given vaginally (the current standard) to that given sublingually. |
| NCT00545194 ↗ | Cervical Ripening Before Induction of Labour at Term: a Randomised Comparison of Prostin vs Propess | Completed | Institut National de la Santé Et de la Recherche Médicale, France | Phase 3 | 2002-01-01 | The aim of this study is to compare two different preparation |
| NCT01635439 ↗ | Prostin and Propess in Induction of Labor | Completed | North West Armed Forces Hospital | Phase 3 | 2010-12-01 | The purpose of the study was to compare the safety and efficacy of two agents used in induction of labor Propess (Controlled release dinoprostone, PGE2, pessary) and Prostin E2 (Dinoprostone vaginal Tablet). |
| NCT01635439 ↗ | Prostin and Propess in Induction of Labor | Completed | Ain Shams University | Phase 3 | 2010-12-01 | The purpose of the study was to compare the safety and efficacy of two agents used in induction of labor Propess (Controlled release dinoprostone, PGE2, pessary) and Prostin E2 (Dinoprostone vaginal Tablet). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for PROSTIN E2
Condition Name
Clinical Trial Locations for PROSTIN E2
Clinical Trial Progress for PROSTIN E2
Clinical Trial Phase
Clinical Trial Sponsors for PROSTIN E2
Sponsor Name
